MedPath

Physiotherapy and Action-Observation Therapy: An Integrated Approach for Upper Limb Impairment in Subacute Stroke

Not Applicable
Withdrawn
Conditions
Stroke
Interventions
Device: Virtual Reality
Device: Landscape video
Device: Action Observation Therapy
Other: Standard treatment
Registration Number
NCT04560764
Lead Sponsor
Fondazione Don Carlo Gnocchi Onlus
Brief Summary

Motor impairment is one of the most common result of a stroke, which causes disability and difficulties in activities of daily living. This motor impairment can concern the upper limb or the lower limb, or both. Several studies investigates the efficacy of different treatment approaches on upper limb and hand function. None of them combined exercise in a virtual context with Action Observation Therapy, consisting in watching an action before doing it.

This study evaluates the addition of Action Observation Therapy (AOT) to Virtual Reality (VR) in the rehabilitation of upper limb impairment in subacute stroke patients. Half of participants will see a video demonstrating the exercise to be performed before its actual execution, while the other half will see a video of a natural landscape followed by the same exercises the other group performs. All the patients will receive additional usual treatment.

Detailed Description

In this study, the intervention will be conducted using a system composed by multiple devices, which are:

* HTC Vive (HTC, headset e Steam station): three-dimensional viewer used for the implementation of the immersive virtual environment, allows both the visualization of the videos and of the exercises to be performed;

* Leap Motion Controller (infrared camera): contactless device for tracking the movement of the patient's fingers and hand;

* Zed Mini (RGB binocular camera and depth camera): Stereo Labs' Zed Mini stereoscopic camera is mounted on the HTC Vive viewer to allow virtual elements to be overlapped within the environment;

* Cometa Wavetrack (transmitter/receiver and Inertial Measurement Units): system for upper limb movement tracking through the use of four wireless inertial sensors applied to the chest, to the arm and to the forearm of the participant through elastic bands and to the hand of the participant through skin-compatible double-sided adhesive patches.

All the devices have been tested to ensure safety of the participants and are provided with the appropriate documentation of declaration of conformity according to the European reference regulations. A careful risk analysis was carried out to ensure the safety of the participants.

All the devices will be working simultaneously during each session of treatment. For the experimental group, the instrumentation will be used to see the video of the exercises that the participants will be later asked to perform and to actually perform them; in the control group, it will be used to see a video of a natural landscape with a 180° perspective and to perform the same exercises than the experimental group.

The devices will be used both for the execution of the exercises both to collect information listed in the outcomes section as secondary outcomes: in particular, these information will be provided by the Leap Motion and by the Cometa Wavetrack devices.

Recruitment & Eligibility

Status
WITHDRAWN
Sex
All
Target Recruitment
Not specified
Inclusion Criteria
  • Participant who suffered from an ictus 3 to 6 months before (subacute phase);
  • Baseline scoring of the Upper Extremity portion of the Fugl Meyer between 20 and 60.
Exclusion Criteria
  • Other neurological pathologies (including previous strokes);
  • Visual field impairments;
  • Neuropsychological deficits that prevents the understanding of the instructions or the execution of the treatment (e.g. aphasia, apraxia, neglect);
  • Baseline scoring of the Mini Mental State Examination (MMSE) lower that 24 (MMSE < 24);
  • Orthopaedic or musculoskeletal limitations that do not allow the execution of the treatment;
  • Clinical instability;
  • Inability to understand the instructions needed to perform the test and the planned evaluations;
  • People with electronic medical devices such as pacemakers;
  • Medical history of epilepsy.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Virtual Reality + Action Observation TherapyVirtual RealityParticipants will see a video demonstrating the exercise they will be later asked to perform. The same procedure is performed for each of the four different exercises.
Virtual Reality + Landscape videoVirtual RealityParticipants will see a video demonstrating a natural landscape and later they will perform an exercise. The same procedure is performed for each of the four different exercises.
Virtual Reality + Action Observation TherapyStandard treatmentParticipants will see a video demonstrating the exercise they will be later asked to perform. The same procedure is performed for each of the four different exercises.
Virtual Reality + Landscape videoLandscape videoParticipants will see a video demonstrating a natural landscape and later they will perform an exercise. The same procedure is performed for each of the four different exercises.
Virtual Reality + Action Observation TherapyAction Observation TherapyParticipants will see a video demonstrating the exercise they will be later asked to perform. The same procedure is performed for each of the four different exercises.
Virtual Reality + Landscape videoStandard treatmentParticipants will see a video demonstrating a natural landscape and later they will perform an exercise. The same procedure is performed for each of the four different exercises.
Primary Outcome Measures
NameTimeMethod
Change of hand dexterityBaseline (T0) and at the end of the treatment (T1, after 4 weeks).

Box and Block test. This test examines hand dexterity measuring the number of wooden blocks the participant is able to move from one box to another with the paretic hand in 60 seconds. Higher values represent a better outcome.

Change of Upper limb functionBaseline (T0) and at the end of the treatment (T1, after 4 weeks).

Upper extremity portion of the Fugl Meyer (UE-FM). This scale measures the function of the upper limb in a range of 0 to 66 points. Higher values represent a better outcome.

Secondary Outcome Measures
NameTimeMethod
Change of reaction timeBaseline (T0) and at the end of the treatment (T1, after 4 weeks).

Seconds from the appearance of the target to the start of the movement. Lower values represent a better outcome.

Change of level completedBaseline (T0) and at the end of the treatment (T1, after 4 weeks).

Most difficult level the participant is able to complete, from 1 to 6. Higher values represent a better performance.

Change of autonomyBaseline (T0) and at the end of the treatment (T1, after 4 weeks).

Barthel Index. This scale measures the ability of the subject to perform activities of daily living. Range 0-100. Higher values represent a better outcome.

Change of Hand Max Reaching VelocityBaseline (T0) and at the end of the treatment (T1, after 4 weeks).

Maximal velocity (meters/seconds) of the hand movement during reaching of the target. Higher values represent a better outcome.

Change of interaction timeBaseline (T0) and at the end of the treatment (T1, after 4 weeks).

Seconds from the appearance of the target to its reaching. Lower values represent a better outcome.

Change of mean time of exercise executionBaseline (T0) and at the end of the treatment (T1, after 4 weeks).

Seconds required for single exercise execution. Lower values represent a better outcome.

Level of SatisfactionAt the end of the treatment (4 weeks).

Likert 1-5. This scale measures the level of satisfaction of the subject regarding the treatment. Higher values represent a better outcome.

Change of quality of LifeBaseline (T0) and at the end of the treatment (T1, after 4 weeks).

EuroQol-5D questionnaire. This questionnaire measures the quality of life. Range 5-15. Lower values represent a better outcome.

Change of number of correct tasksBaseline (T0) and at the end of the treatment (T1, after 4 weeks).

Number of tasks the participants performs correctly. Higher values represent a better performance.

Change of Tip Max DistanceBaseline (T0) and at the end of the treatment (T1, after 4 weeks).

Maximal distance between the thumb and index fingertips.

Change of Tip Max VelocityBaseline (T0) and at the end of the treatment (T1, after 4 weeks).

Maximal velocity of opening and closing between the thumb and index fingertips.

Change of Mean SPARCBaseline (T0) and at the end of the treatment (T1, after 4 weeks).

Spectral parameter related to the smoothness of the movement. Negative values lower than -1 stand for lower smoothness.

Change of % Cycle Hand Max VelocityBaseline (T0) and at the end of the treatment (T1, after 4 weeks).

Dividing the interaction time between the hand and the object into 100 parts, it represents the moment in which the hand reaches the maximal velocity.

Change of Mean Reach Path RatioBaseline (T0) and at the end of the treatment (T1, after 4 weeks).

Parameter calculated as total distance traveled by the wrist of the subject divided by the length of a straight-line path from the reach's starting point (hand resting on the table) to ending point (target). Values equal or close to +1 represent a straight trajectory, while higher values stand for a more curved one.

Trial Locations

Locations (1)

Fondazione Don Carlo Gnocchi Onlus - Centro Ettore Spalenza

🇮🇹

Rovato, Brescia, Italy

© Copyright 2025. All Rights Reserved by MedPath